A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

Summary

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 48 weeks, including screening.

Timeline

Start

2026-04-14

Primary completion

2027-05

Completion

2027-09

Drugs

Indications